Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population- based evaluation

被引:10
作者
Boyle, Jemma M. [1 ,2 ,8 ]
van der Meulen, Jan [1 ,2 ]
Kuryba, Angela [2 ]
Cowling, Thomas E. [1 ,2 ]
Booth, Christopher [3 ]
Fearnhead, Nicola S. [4 ]
Braun, Michael S. [5 ,6 ]
Walker, Kate [1 ,2 ]
Aggarwal, Ajay [1 ,7 ]
机构
[1] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London, England
[2] Royal Coll Surgeons England, Clin Effectiveness Unit, London, England
[3] Queens Univ, Dept Oncol, Kingston, ON, Canada
[4] Cambridge Univ Hosp, Dept Colorectal Surg, Cambridge, England
[5] Christie NHS Fdn Trust, Dept Oncol, Manchester, England
[6] Univ Manchester, Sch Med Sci, Manchester, England
[7] Guys & St ThomasNHS Fdn Trust, Dept Oncol, London, England
[8] Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PE, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
Systemic anti-cancer therapy; Variation; Quality of care; Toxicity; Colorectal cancer; Performance indicator; Quality improvement; IRELAND ACPGBI GUIDELINES; CHEMOTHERAPY TOXICITY; GERIATRIC ASSESSMENT; ADMINISTRATIVE DATA; OLDER PATIENTS; GREAT-BRITAIN; CANCER CARE; ANUS; 2017; PERFORMANCE; BREAST;
D O I
10.1016/j.ejca.2022.10.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To date, there has been little systematic assessment of the quality of care associated with systemic anti-cancer therapy (SACT) delivery across national healthcare sys-tems. We evaluated hospital-level toxicity rates during SACT treatment as a means of identi-fying variation in care quality.Methods: All colorectal cancer (CRC) patients receiving SACT within 106 English National Health Service (NHS) hospitals between 2016 and 2019 were included. Severe acute toxicity rates were derived from hospital administrative data using a validated coding framework. Variation in hospital-level toxicity rates was assessed separately in the adjuvant and metastatic settings. Toxicity rates were adjusted for age, sex, comorbidity, per-formance status, tumour site, and TNM staging.Results: Eight thousand one hundred and seventy three patients received SACT in the adju-vant setting, and 7,683 patients in the metastatic setting. Adjusted severe acute toxicity rates varied between hospitals from 11% to 49% for the adjuvant cohort, and from 25% to 67% for the metastatic cohort.Compared to the national mean toxicity rate in the adjuvant cohort, six hospitals were more than two standard deviations (2SD) above, and four hospitals were more than 2SD below. In the metastatic cohort, six hospitals were more than 2SD above, and seven hospitals were more than 2SD below the national mean toxicity rate.Overall, 12 hospitals (12%) had toxicity rates more than 2SD above the national mean, and 11 (10%) had rates more than 2SD below. Conclusion: There is substantial variation in hospital-level severe acute toxicity rates in both the adjuvant and metastatic settings, despite risk-adjustment. Ongoing reporting of this per-formance indicator can be used to focus further investigation of toxicity rates and stimulate quality improvement initiatives to improve care. 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:191 / 204
页数:14
相关论文
共 61 条
[1]   Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit [J].
Aggarwal, Ajay ;
Nossiter, Julie ;
Parry, Matthew ;
Sujenthiran, Arunan ;
Zietman, Anthony ;
Clarke, Noel ;
Payne, Heather ;
van der Meulen, Jan .
LANCET ONCOLOGY, 2021, 22 (05) :E207-E215
[2]   Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study [J].
Aggarwal, Ajay ;
Lewis, Daniel ;
Mason, Malcolm ;
Purushotham, Arnie ;
Sullivan, Richard ;
van der Meulen, Jan .
LANCET ONCOLOGY, 2017, 18 (11) :1445-1453
[3]   Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score [J].
Armitage, J. N. ;
van der Meulen, J. H. .
BRITISH JOURNAL OF SURGERY, 2010, 97 (05) :772-781
[4]   Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort [J].
Ayanian, JZ ;
Zaslavsky, AM ;
Fuchs, CS ;
Guadagnoli, E ;
Creech, CM ;
Cress, RD ;
O'Connor, LC ;
West, DW ;
Allen, ME ;
Wolf, RE ;
Wright, WE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1293-1300
[5]  
Berwick DM, 2003, MED CARE, V41, pI30
[6]   Development and validation of a coding framework to identify severe acute toxicity from systemic anti-cancer therapy using hospital administrative data [J].
Boyle, Jemma M. ;
Cowling, Thomas E. ;
Kuryba, Angela ;
Fearnhead, Nicola S. ;
van der Meulen, Jan ;
Braun, Michael S. ;
Walker, Kate ;
Aggarwal, Ajay .
CANCER EPIDEMIOLOGY, 2022, 77
[7]   Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients [J].
Boyle, Jemma M. ;
Kuryba, Angela ;
Braun, Michael S. ;
Aggarwal, Ajay ;
van der Meulen, Jan ;
Cowling, Thomas E. ;
Walker, Kate .
CANCER EPIDEMIOLOGY, 2021, 73
[8]   Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset [J].
Bright, Chloe J. ;
Lawton, Sarah ;
Benson, Stephen ;
Bomb, Martine ;
Dodwell, David ;
Henson, Katherine E. ;
McPhail, Sean ;
Miller, Louise ;
Rashbass, Jem ;
Turnbull, Alice ;
Smittenaar, Rebecca .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2020, 49 (01) :15-15L
[9]   Systematic review of discharge coding accuracy [J].
Burns, E. M. ;
Rigby, E. ;
Mamidanna, R. ;
Bottle, A. ;
Aylin, P. ;
Ziprin, P. ;
Faiz, O. D. .
JOURNAL OF PUBLIC HEALTH, 2012, 34 (01) :138-148
[10]   Preoperative radiotherapy for resectable rectal cancer -: A meta-analysis [J].
Cammà, C ;
Giunta, M ;
Fiorica, F ;
Pagliaro, L ;
Craxì, A ;
Cottone, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (08) :1008-1015